AOverview
Alvotech develops and manufactures biosimilar medicines, which are lower-cost versions of biologic drugs used to treat a range of diseases. Its biosimilars are produced through a vertically integrated process, controlling cell line development, manufacturing, and final product steps to ensure quality and efficiency. The company differentiates itself by owning and coordinating the full value chain, enabling tighter cost control, scalable production, and faster delivery of biosimilars to global markets. Alvotech aims to improve lives by making biologic medicines more accessible and affordable, continually evaluating new pipeline opportunities to expand its portfolio and revenue streams.
Work here?Claim your company
About Alvotech
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Reykjavík, Iceland
Founded
2013
Get referred to Alvotech
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA closed Reykjavik inspection as VAI in July 2026, clearing near-term approvals.
- August 2026 Lotus deal adds up to $150 million and Asian commercialization reach.
- Management reaffirmed 2026 revenue guidance of $650 million to $700 million.
What critics are saying
- FDA inspection issues at Reykjavik disrupted supply in H1 2026, crushing revenue.
- Alvotech reported $212 million first-half 2026 revenue, down from $306 million last year.
- Approval delays for AVT05, AVT06, AVT16, and AVT80 threaten 2026-2027 growth.
What makes Alvotech unique
- Alvotech vertically integrates development and manufacturing, controlling cell line through commercial supply.
- By August 2026, Alvotech marketed five biosimilars across Europe, Japan, and the United States.
- Its 30-plus candidate pipeline targets blockbuster biologics and multiple first-wave biosimilar launches.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$2.4B
Above
Industry Average
Funded Over
15 Rounds
Benefits
- Wellness Program
- Home Office Stipend
- Phone/Internet Stipend
- Commuter Benefits
- Company Social Events
- Professional Development Budget
- Flexible Work Hours
Stock Price
Growth & Insights and Company News
6 month growth
0%1 year growth
1%2 year growth
0%Alvotech expands US biosimilar manufacturing with LOTTE. October 8, 2026 Alvotech and LOTTE will expand biosimilar manufacturing capacity in America. Multiple antibody products will use LOTTE's 40,000 litre Syracuse bioreactor infrastructure. Alvotech and LOTTE Biologics have agreed a long term manufacturing partnership that will place production of drug substance for multiple antibody biosimilars at LOTTE's Syracuse facility in New York. The agreement expands Alvotech's external production capacity in the United States while adding another biologics programme to the Syracuse operation. LOTTE will manufacture material for global supply, and the companies may extend the collaboration to further products as the initial programmes move through transfer and manufacturing. Syracuse has 40,000 litres of installed bioreactor capacity alongside process development and quality control capabilities, allowing cell culture production, process support and analytical work to operate within the same manufacturing site. That infrastructure gives Alvotech access to an established regulated facility without waiting for a separate plant to be designed, constructed and qualified. Antibody drug substance is produced biologically through engineered cells grown under controlled conditions inside bioreactors. As the cells multiply and metabolise nutrients they produce the required protein, which is subsequently separated and purified to remove cells, process residues and unwanted proteins before the material moves into later manufacturing stages. Cell culture performance depends on temperature, nutrient concentration, dissolved gases, pH and other operating conditions remaining within defined ranges. Changes in those variables can alter yield and product characteristics, while increasing vessel scale changes mixing, oxygen transfer and heat removal rather than simply reproducing a smaller process at greater volume. The 40,000 litres of installed capacity therefore describes the physical scale of the bioreactors rather than a fixed annual quantity of finished drug substance. Output depends on vessel configuration, duration of each production campaign, cell productivity, purification yield, cleaning and changeover time, and the quantity of material required for each biosimilar. Biosimilar manufacturing adds tight product quality requirements because an antibody has to remain highly similar to its established reference medicine. Large biological molecules contain structural features influenced by the manufacturing process, so producers control critical quality attributes throughout cell culture, purification and analytical testing rather than relying on chemical identity alone. Consistency consequently depends on the complete manufacturing chain from cell banks and media through bioreactor operation, purification and release testing. Each stage has to remain within validated limits across repeated batches, with LOTTE's on site quality control capability providing analytical support while material moves through the Syracuse process. Alvotech already operates large scale biosimilar manufacturing in Iceland, making Syracuse an additional production route rather than a replacement for its existing base. Geographic diversification can reduce dependence on one facility while also creating capacity for a portfolio that includes several antibody products moving through development and commercial supply. US manufacturing can also shorten part of the physical supply chain for products serving the American market, although LOTTE will produce material for global use. Biological drug substance requires controlled handling, validated logistics and regulatory release, so the location of production influences the movement of intermediates and finished material between manufacturing stages. LOTTE acquired the Syracuse site from Bristol Myers Squibb and has developed it as the basis of its US contract development and manufacturing operation. Existing bioreactors, utilities, analytical systems and regulated production infrastructure allow customer programmes to enter an operating site rather than depending on the construction schedule of a new facility. Each Alvotech product will still require process transfer into the Syracuse equipment before routine commercial manufacturing begins. Operating parameters, raw materials, analytical methods and control strategies have to be reproduced on the receiving equipment and shown to deliver product quality consistent with the validated process. Transfer work also has to account for differences in vessel geometry, control systems and supporting equipment between manufacturing locations. Mixing, gas transfer and process timing may require adjustment within validated ranges so the product remains comparable while the process is reproduced on a different production train. Neither company has disclosed the financial value of the partnership, the individual biosimilars covered or the proportion of Syracuse capacity allocated to the programme. Those variables will determine how heavily the agreement loads the facility and how much capacity remains available for other products and customers. Once transfer and qualification are complete, the manufacturing programme will be measured through repeated batch performance rather than nominal bioreactor volume. Stable cell culture, purification yield and analytical results will determine how effectively the installed capacity is converted into saleable biosimilar drug substance across the multiple antibody products covered by the agreement. Stories for you. * Manual vs Powered Lifting Equipment: Which Is Right for Your Application? Choosing suitable lifting equipment depends on more than load capacity. Manual and powered hoists offer different advantages depending on lifting frequency, available power, site conditions and operating costs. Understanding these factors helps businesses select equipment that suits the task while meeting workplace safety requirements. * Industrials remain Europe's second most distressed sector Europe's industrial companies remain among its most financially distressed sectors. The latest Weil index shows corporate pressure still above its long run average.
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply. October 06, 2026 16:37 ET | Source: Alvotech Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnership to increase Alvotech's global manufacturing capacity and support growth in demand REYKJAVIK, Iceland, and SEOUL, South Korea, Oct. 06, 2026 (GLOBE NEWSWIRE) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract development and manufacturing (CDMO) organization, today announced a long-term strategic manufacturing partnership. Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse facility in New York for global supply, with the potential to further expand the collaboration over time. The Syracuse facility has 40,000 liters of bioreactor capacity for biologics manufacturing, supported by on-site process development and quality control capabilities. The site has an established track record in commercial biologics manufacturing and recently completed an unannounced FDA inspection with zero observations, further demonstrating its strong quality and regulatory capabilities. The agreement expands Alvotech's US-based manufacturing footprint while strengthening its global supply network. The additional capacity complements Alvotech's existing manufacturing partnerships and its in-house development and manufacturing capabilities, supporting its expanding portfolio and providing greater flexibility to meet demand across international markets. "Alvotech has one of the most comprehensive, internally developed product portfolios in the industry," said Lisa Graver, CEO of Alvotech. "With the expansion of our global manufacturing network, we will have sufficient capacity to meet demand for our pipeline for the next ten years. Our collaboration with LOTTE Biologics will bring additional manufacturing capacity in New York to support patients worldwide, complementing our existing capabilities as we scale our portfolio and prepare for future launches." "Alvotech's expertise in biosimilar development, combined with LOTTE Biologics' manufacturing capabilities, creates a strong foundation for this collaboration," said James Park, CEO of LOTTE Biologics. "We look forward to strategically supporting Alvotech's growing portfolio and the reliable supply of high-quality, more affordable biologic medicines to patients worldwide. With our Syracuse operations and the completion of our Songdo Bio Campus, we are committed to providing flexible, dual-site manufacturing support as the partnership grows." Commercial supply will be subject to successful technology transfer, manufacturing qualification and applicable regulatory approvals. For further information, contact: Investors Dr. Balaji V Prasad Benedikt Stefansson Mikaela Vilchez [email protected] About Alvotech Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira(R)(adalimumab), Stelara(R)(ustekinumab), Simponi(R)(golimumab), Eylea(R)(aflibercept) and Prolia(R)/Xgeva(R)(denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release. About LOTTE Biologics LOTTE Biologics is a global contract development and manufacturing organization (CDMO) providing an integrated biologics solutions to pharmaceutical and biotechnology companies worldwide. With its established commercial manufacturing operations in Syracuse, New York, and the newly completed Songdo Bio Campus in South Korea, LOTTE Biologics is building a flexible, dual-site manufacturing network to support customers from development through commercial supply. Forward Looking Statements Certain statements in this communication may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech's expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.
Alvotech gains FDA approval for second SIMLANDI production suite. The Reykjavik approval doubles drug substance capacity available for U.S. supply; separate biosimilar applications remain under FDA review. SIMLANDI drug substance can now be made in either of two Reykjavik production suites after Alvotech NASDAQALVO said Monday the U.S. Food and Drug Administration approved a manufacturing supplement for its adalimumab biosimilar. The added suite doubles the drug substance capacity available to support U.S. supply, according to the company's Oct. 5 announcement. The approval adds DSM2 to the existing DSM1 suite as an authorized source for U.S. commercial supply. Alvotech NASDAQALVO shares closed at US$5.45 on Nasdaq at 4 p.m. EDT on Oct. 2, before the announcement. A regular-session share reaction to the Oct. 5 decision was not yet available. Alvotech develops and manufactures biosimilar medicines in Iceland for commercial partners serving markets around the world. SIMLANDI is its U.S. brand for AVT02, an interchangeable biosimilar to Humira approved in 2024, according to the company's joint announcement with its U.S. partner. The Oct. 5 action authorizes another manufacturing source for an already approved medicine. It does not approve any of Alvotech's separate pending U.S. biosimilar applications, which the company says remain subject to their own FDA reviews and decisions. Inspection closure preceded the capacity decision. DSM2 handles cell culture and purification, the stages that produce the drug substance used in the finished medicine. Alvotech said the suite was already approved to make commercial drug substance for European markets, including AVT02, AVT03 and AVT05. U.S. authorization now lets the company allocate AVT02 production between its two Reykjavik suites. "The addition of DSM2 effectively doubles the drug substance manufacturing capacity available to support U.S. supply and provides greater flexibility for commercial supply of AVT02 to the U.S. market," Alvotech chief executive Lisa Graver said in the Oct. 5 release. The company's July 29 inspection update said the FDA had closed its most recent Reykjavik inspection with a Voluntary Action Indicated classification after a May visit. Alvotech describes Monday's supplement approval as further confirmation that the facility's inspection issues were resolved. That account comes from the company release; the FDA's underlying approval letter was not available in the material reviewed. The manufacturing issue had already affected sales. In its Aug. 19 results, Alvotech said its improvement program reduced product availability in the first half of 2026, when adjusted revenue fell to US$211.9 million from US$306.1 million a year earlier. Cash stood at US$142.8 million on June 30, and the company said manufacturing had returned to planned operating levels by the end of that quarter. Teva Pharmaceuticals is Alvotech's U.S. Partner. Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. NYSETEVA, is Alvotech's strategic partner for exclusive U.S. commercialization of SIMLANDI, the companies said in their 2024 approval announcement. The partners said Alvotech handles the product's development and manufacturing. Another U.S. adalimumab biosimilar is AMJEVITA, which Amgen Inc. NASDAQAMGN identifies on its product website as an FDA-approved Humira biosimilar. Both products compete in a treatment category spanning inflammatory conditions, but Monday's FDA action concerned only Alvotech's manufacturing site. The listed U.S. biosimilar names entered Monday from different Oct. 2 closes: Teva NYSETEVA shares were US$39.53 on the NYSE at 4 p.m. EDT. Amgen NASDAQAMGN shares were US$403.04 on Nasdaq at 4 p.m. EDT on Oct. 2. Those prices precede Alvotech's announcement. Alvotech's August update said it anticipated FDA decisions in the fourth quarter of 2026 on resubmitted applications for AVT05, AVT06 and AVT03. The company said in the Oct. 5 release that those applications remain subject to individual decisions, so the SIMLANDI supplement establishes no outcome for them. Alvotech is scheduled to release third-quarter results on Nov. 11. That report will show whether its return to planned manufacturing levels lifted product revenue before the separate FDA decisions it expects in the fourth quarter.
Alvotech (NASDAQ:ALVO) trading up 7.2% - should you buy? September 18, 2026 Key points. * Alvotech shares rose 7.2% to $5.7250 in Friday midday trading, with a market capitalization of approximately $1.80 billion. * Analyst sentiment is generally positive: the stock has a "Moderate Buy" consensus rating from eight analysts and an average price target of $8.50, although ratings include one Sell recommendation. * The company exceeded revenue expectations in its latest quarter with $106 million, but missed on earnings per share and remains unprofitable, reporting a net margin of -36.31%. * MarketBeat previews the top five stocks to own by October 1st. Shares of Alvotech (NASDAQ:ALVO - Get Free Report) were up 7.2% on Friday. The stock traded as high as $5.65 and last traded at $5.7250. Approximately 704,465 shares changed hands during mid-day trading, a decline of 0% from the average session volume of 704,637 shares. The stock had previously closed at $5.34. Wall Street analysts forecast growth. A number of equities research analysts have commented on the stock. Wall Street Zen downgraded shares of Alvotech from a "hold" rating to a "sell" rating in a research report on Saturday, May 23rd. Evercore began coverage on Alvotech in a research note on Friday, August 14th. They issued an "outperform" rating on the stock. Weiss Ratings raised Alvotech from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, August 31st. Barclays upgraded Alvotech from an "underweight" rating to an "overweight" rating and upped their price objective for the company from $4.00 to $8.00 in a research report on Wednesday. Finally, UBS Group set a $8.00 price target on Alvotech in a research note on Wednesday. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $8.50. Alvotech trading up 11.8%. The stock has a market capitalization of $1.80 billion, a P/E ratio of -9.78 and a beta of 0.22. The business has a 50-day moving average price of $4.23 and a 200 day moving average price of $3.81. Alvotech (NASDAQ:ALVO - Get Free Report) last posted its quarterly earnings data on Thursday, August 20th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.06). Alvotech had a negative net margin of 36.31% and a negative return on equity of 11.92%. The firm had revenue of $106.00 million for the quarter, compared to the consensus estimate of $103.00 million. On average, sell-side analysts predict that Alvotech will post 0.01 earnings per share for the current fiscal year. Institutional inflows and outflows. Several large investors have recently modified their holdings of the company. Citadel Advisors LLC purchased a new position in Alvotech during the 2nd quarter worth $6,376,000. Renaissance Technologies LLC increased its stake in shares of Alvotech by 146.9% in the first quarter. Renaissance Technologies LLC now owns 63,200 shares of the company's stock worth $217,000 after acquiring an additional 37,600 shares during the period. Finally, ProShare Advisors LLC raised its stake in shares of Alvotech by 24.0% during the 4th quarter. ProShare Advisors LLC now owns 13,826 shares of the company's stock valued at $71,000 after buying an additional 2,675 shares during the last quarter. About Alvotech. Alvotech is a biopharmaceutical company headquartered in Reykjavik, Iceland, focused on developing and manufacturing biosimilar medicines. Its products are intended to provide alternatives to biologic therapies used to treat conditions including autoimmune diseases, cancer and eye disorders. The company has established a pipeline spanning several therapeutic areas, with candidates targeting medicines such as ustekinumab, denosumab, secukinumab and aflibercept. Alvotech operates an integrated platform covering cell-line development, process development, analytical testing and commercial-scale manufacturing. Founded in 2013, Alvotech serves international markets through commercial and strategic partnerships. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Alvotech, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alvotech wasn't on the list. While Alvotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom. Continue following MarketBeat
Alvotech stock edges lower as biosimilar specialist holds USD 1.31 billion market cap. Published on 09/04/2026 at 18:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Alvotech stock is trading modestly lower around USD 5.35, while the Iceland based biosimilar specialist maintains a market capitalization of about USD 1.31 billion and remains a niche peer to larger pharma names such as Teva Pharmaceutical Industries. Alvotech stock (ISIN LU2557688560) closed at 5.35 USD on Nasdaq as of September 3, 2026, a decline of 0.03 USD or 0.56% on the day according to market data compiled by Yahoo Finance. As of August 2026, the company is valued at about 1.31 billion USD in market capitalization, based on a share price around 3.88 USD reported by CompaniesMarketCap, underscoring the companys position as a mid cap player in the global biosimilars market. Market data and peer context. The latest available quote for Alvotech stock at 5.35 USD as of September 3, 2026 places the shares notably above the 3.88 USD level used by CompaniesMarketCap to calculate the 1.31 billion USD valuation as of August 2026, implying that the current market capitalization is likely somewhat higher than that earlier snapshot while remaining in the same broad range of around 1.3 billion USD according to the two datasets. For retail investors, this comparison shows that the stock has appreciated by roughly 1.47 USD from the reference price used in the August valuation to the closing price reported at the start of September 2026, a gain of about 37.9% over that period in pure price terms. While Alvotech focuses specifically on biosimilar development and manufacturing, larger diversified pharmaceutical peers illustrate the wider sector backdrop. Teva Pharmaceutical Industries American Depositary Receipts recently traded at 36.47 USD on the New York Stock Exchange as of September 3, 2026, according to a quote page on MarketWatch, showing how significantly larger incumbents in generic and specialty medicines carry much higher absolute share prices and market capitalizations than Alvotech. For investors evaluating Alvotech, this contrast highlights that the company remains a smaller, more focused biosimilar pure play compared with such multi segment peers. Analyst style signals and valuation perspective. Beyond raw price movements, quantitative assessments give an additional angle on how Alvotech stock is currently perceived. An AI driven comparison between Alvotech and GE HealthCare compiled by the analytics platform Danelfin indicates an implied price target of 5.34 USD for Alvotech, with a high forecast of 7.01 USD and a low forecast of 3.47 USD, summarizing a range of model based scenarios for the shares and positioning the current 5.35 USD closing price very close to that central target level as of early September 2026. The fact that the latest quote stands just above the algorithmic target can be read as a signal that the market has already moved toward the level suggested by such quantitative tools, while leaving room for potential upside or downside within the projected interval. Given a market capitalization near 1.31 billion USD as of August 2026 and a share price that has risen from around 3.88 USD to 5.35 USD within roughly one month, investors can infer a tightening valuation band in which expectations for Alvotechs biosimilar pipeline and manufacturing platform are increasingly reflected in the stock price. The comparison versus the AI target range also underscores that the shares currently trade within the models corridor rather than at a deep discount or extreme premium, suggesting a relatively balanced risk reward profile in the absence of sharp near term catalysts. More data and background on Alvotech. Investors who want to explore additional fundamentals, filings and trading history for Alvotech stock can use the ad hoc news topic overview and the companys own investor relations resources. Biosimilar portfolio as growth driver. Alvotech, headquartered in Reykjavik, focuses on developing and producing biosimilar medicines, which are highly similar versions of already approved biological drugs used in therapy areas such as autoimmune diseases, oncology and other chronic conditions. While the latest quarter or fiscal year figures are not explicitly detailed in the day filtered search results, the companys strategy centers on building a portfolio of biosimilars to major reference products, thereby targeting both volume growth and margin expansion as healthcare systems and payers increasingly favor cost efficient alternatives to originator biologics. Biosimilars can offer price reductions versus reference biologic drugs while maintaining comparable efficacy and safety profiles, making them an important lever for containing healthcare spending. For Alvotech, each successfully launched biosimilar represents a potential multi year revenue stream tied to the underlying reference products market size. The companys manufacturing capabilities and quality track record are therefore key to capturing share in tenders and reimbursement decisions, especially in Europe and North America where biosimilar adoption is most advanced. Stock positioning and investor takeaways. With Alvotech stock at 5.35 USD as of September 3, 2026 and a market capitalization of about 1.31 billion USD as of August 2026, the shares currently sit in a valuation zone that reflects both the risks and opportunities of a focused biosimilar specialist. The roughly 37.9% increase from the 3.88 USD level used in the August market cap snapshot to the early September closing price shows that the market has recently repriced the stock, although the day to day move on September 3, 2026 itself was a modest decline of 0.56%. For investors, this constellation means that short term price volatility is likely to be driven by news on regulatory approvals, launch timings, manufacturing performance and partnership structures rather than broad sector trends alone. The AI based target of 5.34 USD sits almost exactly at the current price, suggesting that quantitative models see Alvotech as fairly valued in the near term, while the wider forecast band between 3.47 USD and 7.01 USD highlights the range of possible outcomes depending on how individual biosimilar projects progress. Alvotech key data. * Company: Alvotech S.A. * ISIN: LU2557688560 * Ticker: ALVO * Trading venue: Nasdaq (USA) * Price (as of September 3, 2026): 5.35 USD * Market capitalization: 1,310,000,000 USD (as of August 2026) * Sector / Industry: Pharmaceuticals / Biotechnology * Index membership: not part of major blue chip indices Alvotech on social and video platforms. Sponsored Ad Turbulent markets: How smart investors protect their portfolio now. While many investors get nervous, experienced investors use the current market situation to their advantage. A current special report from 5 September shows the strategies to make your portfolio crisis-proof - and even profit from volatility. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | LU2557688560 | ALVOTECH | boerse | 70055676 | bgmi
Alvotech is Hiring for 14 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Alvotech
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Reykjavík, Iceland
Founded
2013
Alvotech is Hiring for 14 Jobs on Simplify!
Find jobs on Simplify and start your career today